Drug intelligence / Profile preview

HL016

Development stage: Unknown
Lead developer: Huili Pharmaceutical
Modality: Small Molecules
Administration: Intramuscular

Overview

HL016 is an investigational long-acting injectable microsphere formulation of donepezil hydrochloride, an acetylcholinesterase inhibitor. Developed by Huili Pharmaceutical (Suzhou) and Bestcan (Hangzhou) Biopharmaceutical, it is intended for the treatment of mild to moderate Alzheimer's disease. The microsphere technology allows for sustained release of the active drug, potentially reducing the frequency of administration and improving patient adherence compared to daily oral donepezil. It is currently undergoing Phase 1 clinical trials in China to evaluate its safety, tolerability, and pharmacokinetic profile in comparison to donepezil hydrochloride tablets.

Other names: donepezil hydrochloride long-acting injectiondonepezil microspheres

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on HL016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HL016.

Explore the full profile